Physician profile
Vincent Avila
NPI 1518965110
$3,585.02
in general payments reported to CMS, 2019-2025
23 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $328 · 2021: $681 · 2022: $831 · 2023: $289 · 2024: $463 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164 · Education: $27.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.41 |
| Education | $27.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $463.34 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals LP | $451.30 | 2019-2023 | Farxiga |
| Akebia Therapeutics INC | $399.52 | 2020-2025 | Vafseo |
| Fresenius USA Marketing, INC. | $371.19 | 2019-2024 | Velphoro |
| Horizon Therapeutics Plc | $315.81 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $304.40 | 2020-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $188.36 | 2019-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $186.47 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $117.82 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $104.15 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $99.38 | 2022-2025 | |
| Vifor Pharma, INC. | $99.26 | 2021-2022 | |
| Ardelyx, INC. | $91.72 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $70.65 | 2022-2024 | Rayaldee |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $44.52 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $42.78 | 2022-2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $23.44 | 2023 | |
| Renalytix Ai, INC. | $20.04 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $19.88 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.25 | 2022 | |
| Shire North American Group INC | $13.19 | 2019 | |
| Rockwell Medical, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.